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Abstract
Background: A decline in hemoglobin (Hb) concentration during antiviral therapy in chronic hepatitis C (CHC) is a
serious side effect. It may compel to dose reduction or even termination of antiviral treatment. The activation of
erythropoietin (EPO) synthesis as a physiological response to anemia and its relation to a genetic variation within
the EPO gene has not been evaluated yet.
Methods: Data of 348 CHC patients were reviewed retrospectively. Samples were genotyped for EPO rs1617640
and inosine triphosphatase (ITPA) rs1127354. Serum EPO concentrations were determined before and during therapy.
Primary endpoints were set as Hb decline >3 g/dl at weeks 4 and 12.
Results: EPO rs1617640 G homozygotes showed a significantly lower rise of serum EPO level over time than T allele
carriers (p < 0.001). The cumulative frequency of a significant Hb reduction added up to 40%. Multivariate analysis
revealed that besides age, ribavirin starting dose and baseline Hb also EPO rs1617640 G homozygosity associates
with Hb reduction at week 4 (p = 0.025) and 12 (p = 0.029), while ITPA C homozygotes are at risk for Hb decline
particularly early during treatment. Furthermore, EPO rs1617640 G homozygotes were more frequently in need for
blood transfusion, epoetin-α supplementation, or ribavirin dose reduction (p < 0.001).
Conclusions: Our data suggest that EPO rs1617640 genotype, the rise of serum EPO concentration as well as ITPA
rs1127354 genotype are promising parameters to evaluate the Hb decline during antiviral therapy. A rational
adjustment of therapy with epoetin-α supplementation might prevent serious adverse events or the need to
terminate treatment.
Keywords: Anemia, Chronic hepatitis C virus infection, Ribavirin, EPO promoter polymorphism rs1617640, ITPA
rs1127354
Background
Antiviral combination therapy consisting of pegylated
interferon-α and ribavirin (PEG-IFN-α/RBV) for treat-
ment of chronic hepatitis C virus (CHC) infection is
highly effective but it is also difficult to tolerate in some
patients. In fact, it is associated with significant morbid-
ity and with treatment-limiting adverse events [1]. One
important treatment-limiting adverse event is anemia.
In various prospective trials dose modification of RBV
because of hemoglobin (Hb) reduction were required in
9% up to 22% of patients [2,3] affecting the overall treat-
ment outcome. Recently, clinical studies assessing effi-
cacy of HCV protease inhibitors in combination with
PEG-IFN-α/RBV revealed an even higher rate of anemia
ranging between 27%-46% [4,5]. Moreover, the need to
administer erythropoietin (EPO) was also increased
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IFN-α monotherapy may induce a significant and rapid
Hb decrease most probably caused by bone marrow in-
hibition [6]. RBV, by contrast, contributes to anemia by
increasing hemolysis [7]. Several reports have examined
serum EPO levels during antiviral treatment and could
show an increase up to 4-fold at week 4 in patients
treated with PEG-IFN-α2a and RBV while Hb levels are
declining [8-12]. In the study by Trivedi et al. [10] the
mean EPO serum level increased from 14.5 ± 15.1 at
baseline to 58.5 ± 94.1 mIU/ml at week 4 in 43 chronic
HCV infected patients treated with antiviral combin-
ation therapy. Durante et al. [12] investigated EPO
serum concentrations during antiviral combination ther-
apy related to Hb decrease in 18 chronic HCV patients.
The mean EPO serum level at the Hb nadir was 55.5 ±
30.5 mIU/ml. Another study could also show that the
median EPO serum level increased at week 12 to 41
mIU/ml (range 12–683 mIU/ml) in 145 patients with
chronic hepatitis C during PEG-IFN-α and RBV therapy
[9,10]. Of note, a genetic variation within the EPO gene
promoter region, rs1617640, was reported to be related
to EPO concentration in the vitreous body fluid of non-
diabetic patients [13]. In 2010, a genome-wide associ-
ation study revealed that two functional variants in the
inosine triphosphatase (ITPA) gene causing ITPA defi-
ciency protect against RBV-induced hemolytic anemia
and the need for RBV dose reduction in patients with
HCV genotype 1 infection [14]. Recently, various studies
could confirm these findings in CHC genotype 1 to 4
infected patients [15-18]. ITPA variants could predict Hb
decline during therapy in patients treated with PEG-
IFN-α/RBV as well as in patients treated Telaprevir and
PEG-IFN-α/RBV [19]. However, the exact mechanism of
Hb reduction under combined antiviral therapy in CHC
patients is still not fully understood.
This study sought to extend the understanding of Hb
decline in CHC patients undergoing antiviral combin-
ation therapy. For this purpose, Hb and serum EPO con-
centrations were monitored before and at week 4, 8 and
12 after onset of antiviral combination therapy and re-
lated to EPO rs1617640 and ITPA rs1127354 genotypes.
Methods
Patients and inclusion criteria
Patients were included in this retrospective analysis in
which core data and samples were collected before and
on treatment. Inclusion criteria for this analysis were
HCV-RNA positivity for more than 6 months, treatment
with PEG-IFN-α and RBV, age 18 years or older, and
compensated liver disease (Child-Pugh score <7). Also
blood samples for genotyping and complete data sets for
pre- and on-treatment (week 4, 8 and 12) Hb values
had to be available. Patients with active hepatitis B virus
or human immunodeficiency virus infection, continued
alcohol or drug abuse and those who also received im-
munosuppressive drug agents were excluded from the
study. 348 patients fulfilled the above criteria and were
included in the analysis. This study was approved by the
ethics committee of the University Medical Center of
Goettingen (initial approval number 4/8/93 and subse-
quent amendments). All patients gave their written in-
formed consent to participate in the study in accordance
with the ethical guidelines of the 1975 Declaration of
Helsinki. Patients also gave their written informed con-
sent to perform EPO rs1617640 and ITPA rs1127354
genetic testing. Further disease chronicity was defined
histopathologically by using established criteria [20]. In
patients, who refused liver biopsy, chronicity was docu-
mented by longitudinal observation and/or the results of
clinical, biochemical and imaging results. Before the ini-
tiation of therapy, a liver biopsy was obtained from 249
patients. On the basis of histological, biochemical and
imaging results 48 individuals had evidence of severe
fibrosis and cirrhosis. 15 out of 99 individuals who
refused liver biopsy had indirect signs of cirrhosis by
clinical, biochemical and imaging results.
Treatment regimen and definition of efficacy
Patients received 1 of 3 treatment regimens (Table 1): (1),
PEG-IFN-α2b 1.5 μg/kg/week (wk) (standard dose) or (2),
PEG-IFN-α2b 1.0 μg/kg/wk (low dose), both in combin-
ation with oral RBV dosed by body weight (40 – 65 kg,
800 mg/day; >65– 85 kg, 1000 mg/day; >85– 105 kg,
1200 mg/day; >105–125 kg, 1400 mg/day); or (3), PEG-
IFN-α2a 180 μg/wk plus oral RBV 1000 – 1200 mg/day
dosed by body weight (<75 kg, 1000 mg/ day; ≥75 kg,
1200 mg/day). RBV dose was adjusted to body weight but
not to viral genotypes, according to two recent studies in
the field [21,22]. PEG-IFN-α2a and PEG-IFN-α2b dose was
reduced when WBC and/or platelet counts fell below
1,500×103 cells/μl or 50,000×103 cells/μl respectively.
Dose modifications of weekly PEG-IFN-α2a were made by
decremental adjustments of 180 μg to 135 μg and 90 μg.
PEG-IFN-α2b dose was reduced to 1.0 μg/kg/week or
replaced by 0.5 μg/kg/week PEG-IFN-α2b. RBV dose was
reduced if Hb was <10 g/dl or when patients complained
of symptoms. Dose modification of daily RBV dose was
performed in decrements of 200 mg.
Data collection and treatment of anemia
Clinical examination, total blood cell counts and routine
biochemical tests and efficacy assessments were per-
formed during the treatment period every 2 weeks
during the first 12 weeks, then four-weekly until week
48 and, finally, at weeks 4 and 24 during follow-up. At
these time-points, serum samples were obtained and
stored at −20°C until further use. Serum samples were
collected from 2003 to 2012.
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When and how to treat anemia was essentially left at
the discretion of the physician who treated the patient.
Center specific standard operating procedures advised
that treatment should be initiated when Hb dropped
below 10 g/dl or when the patient complained of symp-
toms. At the discretion of the physician anemia could
be treated by blood transfusions, epoetin-α supplemen-
tation, RBV dose reduction or a combination thereof.
During treatment the physician in charge was unaware
to patients’ ITPA and EPO genotypes and EPO serum
concentrations as these analyses were performed only
after completion of treatment.
Study end points
In accordance with previous analyses [14] we analyzed
Hb reduction of >3 g/dl. Differently to these previous
analyses we did not only consider Hb reduction at week
4 weeks but also at week 12 as a composite endpoint,
i.e., occurrence of an end point at either one of the
time points. Furthermore, we analyzed RBV dose reduc-
tion, administration of blood transfusions or epoetin-α
supplementation within 12 weeks of treatment as a
composite event.
Specific laboratory procedures
Detection of serum HCV-specific RNA by RT-PCR
and determination of HCV genotypes were performed
as described earlier [23,24]. Serum HCV-RNA was mon-
itored monthly.
Isolation of genomic DNA and single nucleotide poly-
morphism (SNP) genotyping were performed as de-
scribed earlier [25]. Genotyping of EPO rs1617640 was
performed by using the following primer: 36 μmol/l of
each primer in each case; forward, 5′-AGC TAA GGT
TTT ATG GCT TCT GGA A-3′; reverse 5′-GGT CTC
CTG CTC TGG GAA TC-3′. Allelic discrimination was
achieved by adding 8 μmol/l differentially fluorescent
dye-labeled allele-specific minor groove binder probes
(EPO: VIC, 5′-CTG AGC CAG AGG AGT GA-3′;
FAM, 5′-CTG AGC CAG ATG AGT GA-3′). Genotyp-
ing of ITPA rs1127354 (ABI; NO: C_27465000) was per-
formed according to the manufacturer’s instruction.
Serum levels of EPO were measured using the Quantikine
human EPO enzyme linked immunosorbent assay (ELISA;
R&D Systems, Articel-Nr: DEPOO). The assays were per-
formed according to the manufacturer’s instructions.
Statistical analyses
For this exploratory statistical analysis P-values of less
than 0.05 were considered as statistically meaningful. In
general, continuous variables are presented with median
and interquartile range (IQR) and were analyzed by the
non-parametric Mann–Whitney-U test [26]. Binary and
categorical variables were compared by Pearsons chi-
squared test or the Cochran-Armitage Trend Test in case
of ordered categorical variables [27]. Hardy-Weinberg-
equilibrium was tested by likelihood ratio test [28].
Multivariate logistic regression included variables that
have been reported to influence Hb in patients on treat-
ment, such as age, sex, and pre-treatment Hb, viral geno-
type, and ribavirin starting dose [29,30]. The major allele
of a SNP was considered to be the baseline allele (CC
for ITPA rs1127354 and TT for EPO rs1617640). We
primarily considered an additive genotype model for
ITPA rs1127354 and a recessive model for EPO rs1617640
(with respect to the minor allele) as suggested from previ-
ous analyses [13,14,31], but dominant and co-dominant
models were also considered. Backward stepwise model
selection was performed based on the Akaike information
criterion (AIC) [32]. The estimates are reported as odds
Table 1 Baseline patient characteristics (n = 348)
Female sex, n (%) 126 (36)
Age [median (IQR)] years 50 (43 – 58)
Ethnicity Caucasian, n (%) 346 (99)
HCV genotype 1/2/3 (%) 240/25/83 (69/7/24)
ALT [median (IQR)] U/l 49 (28 – 86)
Hb [median (IQR)] g/dl 15.1 (14.2 – 16)
Creatinine [median (IQR)] mg/dl 0.8 (0.7 – 0.9)
EPO# [median (IQR)] mIU/ml* 7.8 (6 – 10.5)
Hepatitis activity mild, n (%) 170 (68)
Fibrosis absent or mild, n (%) 201 (81)
Severe Fibrosis or Cirrhosis1, n (%) 631 (18)
Steatosis absent or mild, n (%) 224 (90)
Initial daily RBV dose2, n (%)
800 mg 37 (10)
1.000 mg 125 (36)
1.200 mg 110 (32)
1.400 mg 76 (21)
PEG-IFN-α treatment, n (%)
PEG-IFN-α2a 238 (68)
PEG-IFN-α2b 1.0 μg/kg 30 (9)
PEG-IFN-α2b 1.5 μg/kg 80 (23)
SVR by genotype 1/2/3, n (%) 101/20/68 (42/80/82)
EPO rs1617640 TT/TG/GG, n (%) 113/168/67 (33/48/19)
ITPA rs1127354 CC/CA/AA, n (%) 280/66/2 (80/19/1)
Data are given as median and interquartile range, if not indicated
otherwise. 249 patients undergone histological evaluation; #Pretreatment
serum EPO measurement was available in 181 patients: *Normal range:
3.3-16.6 mIU/ml; 148 patients with histological signs of severe fibrosis or
cirrhosis and 15 patients with clinical, biochemical and imaging evidence
of severe fibrosis or cirrhosis. 2Initial daily RBV dose was weight-based on a sliding
scale in subjects’ baseline weight. Abbreviations: HCV hepatitis C virus, γ-GT
gamma-glutamyltransferase, ALT alanine transaminase, RBV ribavirin, PEG-IFN-α
pegylated interferon-α, SVR sustained virological response, EPO erythropoietin,
ITPA inosine triphosphatase.
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ratios (OR) with confidence intervals and P-values based
on the likelihood ratio. An OR above one indicates a
higher risk of anemia in patients with the corresponding
trait.
A linear model for the development of erythropoietin
levels over time was fitted with an interaction factor of
time and the minor allele of EPO rs1617640. A signifi-
cant interaction of time and the EPO gene variant in this
model indicates a different development of erythropoi-
etin for patients being homozygous for the minor allele
compared to patients being heterozygous or homozy-
gous for the major allele. Because of repeated measure-
ments we confirmed the analysis in a mixed model.
P values cited were obtained from likelihood ratio test.
All statistical analyses were performed using the R lan-




A total of 348 patients were included in this study. Base-
line demographic, biochemical, and virological charac-
teristics of the study cohort are listed in Table 1.
The two polymorphisms of interest, EPO rs1617640
and ITPA rs1127354, were genotyped in all patients
(Table 1); genotype distributions met Hardy-Weinberg-
equilibrium (EPO rs1617640 p = 0.75; ITPA rs1127354
p = 0.33). The resulting minor allele frequencies (MAF) of
0.434 and 0.101 for EPO rs1617640 (allele G) and ITPA
rs1127354 (allele A), respectively, were close to those re-
ported for healthy Caucasian controls [13,14].
Serum EPO concentrations and incidence of marked Hb
decline with regard to EPO rs1617640 genotypes
Serum EPO concentrations at baseline were available
for 181 individuals, all of them found to be within the
normal range (Table 1). During therapy, concentrations
raised 5-fold by week 4 (median 43.2 mIU/ml, IQR 28.70
to 68.25) and 14-fold by week 8 (median 106.20 mIU/
ml, IQR 65.45 to 160.5). EPO rs1617640 G homozygotes
had similar baseline serum EPO concentrations when
compared to T allele carriers (Figure 1). A linear model,
however, revealed a lower rise over time in G homozy-
gotes (p < 0.001 for interaction of time and gene variant
in simple linear model and p = 0.008 in a linear mixed
effects model, Figure 1).
At baseline, patients’ median Hb concentration was
within the normal range (15.1 g/dl, IQR 14.2 to 16.0 g/dl).
Median Hb concentration declined at week 4, 8 and 12
by −1.8 (IQR 12.1 to 14.2 g/dl, p < 0.001), −2.4 (IQR 11.4
to 13.6 g/dl, p < 0.001) and −2.6 (IQR 11.1 to 13.4 g/dl,
p < 0.001), respectively. The cumulative frequency of pa-
tients with Hb reductions > 3 g/dl at week 4, 8 and 12 was
25%, 32% and 40%, respectively (data not shown). Median
baseline Hb levels of G homozygotes were 14.7 g/dl (IQR





















Figure 1 Pre- and on-treatment serum EPO levels with regard to EPO rs1617640 genotypes. Pretreatment serum EPO concentrations
were equally distributed among major T allele carriers and minor G homozygotes. On-treatment serum EPO concentrations of EPO rs1617640 G
homozygotes and T allele carriers at week 4 and 8 of therapy, however, differed significantly in a linear model. Data on serum EPO concentrations
were available in 181, 112 and 78 individuals at week 0, 4 and 8, respectively. Medians and IQRs are given.
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14.2 to 16.1) (p = 0.088). Median baseline hematocrit levels
of G homozygotes were 44% (IQR 42 to 45) and of T
homo- and heterozygotes 43% (IQR 41 to 46) (p = 0.48).
With regard to EPO rs1617640 genotypes, G homozygotes
experienced more frequently a marked Hb decline than
T allele carriers (Figure 2A). In a univariate analysis, this
difference did not reach statistical significance (p = 0.09,
p = 0.09 and p = 0.1 for weeks 4, 8 and 12, respectively). In
multivariate logistic regression analyses, EPO rs1617640
allele G associates with an increased risk of Hb reduction
of more than 3 g/dl at week 4 (odds ratio (OR) 2.17, confi-
dence interval (CI) 1.09 to 4.3, p = 0.025) (Table 2) and
week 12 (OR 1.97, CI 1.07 to 3.66, p = 0.029) (Table 2) of
therapy, respectively. A linear regression analysis revealed
the increase of serum EPO levels to be inversely associated
with the decline of Hb levels at week 4 (Figure 3A).
Stratification for EPO rs1617650 genotypes revealed
this inverse correlation to be valid for T allele carriers
(Figure 3C) but not for G homozygotes (Figure 3B).
Data thus support an impact of this polymorphism on
the relationship of serum EPO and Hb levels. In addition,
older age, higher Hb values and higher RBV dose at the
onset of therapy significantly increase the risk of patients
to have Hb reduction at 4 and 12 weeks (Table 2), whereas
viral genotype had no significant effect on Hb reduction
(data not shown).
Clinical endpoints with regard to EPO rs1617640 genotypes
Epoetin-α supplementation, RBV dose reduction or
blood transfusions were indicated in 14%, 5%, and 4%
of patients, respectively. All three Hb reconstitution
measures were analyzed as a composite event. An ana-
lysis with regard to EPO rs1617640 genotypes revealed
40% of G homozygotes to be affected by at least one of
these events compared to only 14% of the T allele car-
riers (p < 0.001, Table 3). Also in multivariate logistic
regression, the EPO rs1617640 G allele strongly associ-
ated with a higher risk of an event (p < 0.001) such as
RBV dose reduction and epoetin-α supplementation.
When we decompose the composite event and look at
the single end-points we observed a significant effect of
EPO rs1617640 on epoetin-α supplementation and RBV
dose reduction (p < 0.001 for both in Pearsons chi-
squared test), but not for blood transfusions (p = 0.366).
Hb levels of EPO rs1617640 G homozygotes and the
need for epoietin-α supplementation remained stable be-
tween week 4 (11 g/dl), 8 (11.4 g/dl) and 12 (11.5 g/dl),
respectively. Other factors that are associated with the
risk of a clinical event are sex (female sex: OR 0.41, CI
0.21 to 0.80, p = 0.003) and RBV starting dose (OR 1.18,
CI 1.01 to 1.39, p = 0.036) but not baseline Hb (Table 4).
While our data revealed an association of EPO rs1617640
genotypes and the need for Hb reconstitution measures as
one clinical endpoint, they did not unveil any relationship
to baseline Hb level or to other clinical endpoints as histo-
logical stage of liver disease or antiviral treatment outcome
(data not shown).
Laboratory and clinical parameters with regard to ITPA
rs1617640 variants
The overall incidence of Hb reduction of more than 3 g/dl
increased steadily over a period of 12 weeks during treat-
ment (Figure 2). ITPA rs1127354 C homozygotes showed
an Hb reduction >3 g/dl at week 4, 8 and 12 of 27%,
39% and 50%, respectively (Figure 2B). The risk of de-
creasing Hb levels >3 g/dl was significantly higher in ITPA
rs1127354 C homozygotes compared to T allele carriers
during treatment at week 4 (p = 0.005), but less pro-





























Patients with Hb reduction > 3 g/dlA
B
Figure 2 Cumulative proportion of patients with an Hb
reduction >3 g/dl during antiviral combination therapy with
regard to EPO rs1617640 (A) and ITPA rs1127354 (B) genotypes.
A marked Hb reduction was more frequent among EPO rs1617640
minor allele G homozygotes and ITPA rs1127354 major allele C
homozygotes than among EPO rs1617640 T allele and ITPA
rs1127354 A allele carriers.
Amanzada et al. BMC Infectious Diseases 2014, 14:503 Page 5 of 10
http://www.biomedcentral.com/1471-2334/14/503
The Cochran-Armitage trend test indicated an effect
of ITPA rs1127354 C allele carriers on Hb reduction at
week 4 and only marginally at week 12, with the minor
allele A ameliorating anemia (p = 0.005 and p = 0.056,
respectively). In multivariate logistic regression ITPA
rs1127354 gene variant is associated with decreased risk
of Hb reduction at week 4 (OR 0.32, CI 0.13 to 0.7,
p = 0.007) but not at week 12 (OR 0.58, CI 0.32 to 1.03,
p = 0.067) (Table 2). ITPA gene variation had no signifi-
cant effect on clinical endpoints such as epoetin-α sup-
plementation, RBV dose reduction or blood transfusions
(p = 0.079) (Table 3). No interactions between EPO
rs1617640 and ITPA rs1127354 could be shown by like-
lihood ratio test.
Discussion
The major findings of the present study are: (1) serum
EPO levels of all individuals increased significantly 5-fold
at week 4 and 14-fold at week 8 compared to baseline, (2)
EPO rs1617640 G homozygotes showed significantly lower
serum EPO levels during antiviral treatment compared to
T allele carriers, (3) besides age, baseline Hb levels and
RBV dose, EPO rs1617640 G allele is independently asso-
ciated with Hb decline during antiviral treatment, (4) in
EPO rs1617640 G homozygotes the need of RBV dose
reduction as well as epoetin-α supplementation was sig-
nificantly higher compared to T allele carriers, (5) ITPA
rs1127354 gene variant rather associated with Hb reduc-
tion at week 4 but not at week 12 and did not increase the
risk of epoetin-α supplementation, RBV dose reduction or
blood transfusion.
Hb decline during antiviral treatment is a frequent side
effect and the reason for it is probably multifactorial.
IFN-α induces a significant and rapid dose-dependent
Hb decline in CHC patients probably by causing an
inhibition of hematopoietic stem cell proliferation [6,34,35].
Accumulation of RBV in red blood cells may aggravate
anemia by inducing hemolysis.
The most important mediator of erythropoiesis is EPO.
Several reports have examined serum EPO levels during
antiviral treatment and could show that serum EPO levels
are increasing up to 4-fold at week 4 in patients treated
with PEG-IFN-α and RBV while Hb levels are declining
[10,12]. Our present study is consistent with these results
in this respect. Here, we examined for the first time a sin-
gle nucleotide polymorphism (SNP) within the EPO gene
promoter, rs1617640 [13], in chronic hepatitis C patients
who were undergoing antiviral treatment. The T allele of
this polymorphism had been shown to be associated with
higher levels of EPO in the vitreous body fluid of non-
diabetic patients than the G allele [13]. The present study
found EPO rs1617640 G homozygotes to have an attenu-
ated serum EPO response compared to T allele carriers.
Moreover, EPO rs1617640 G homozygotes also had higher
incidence of significant Hb reduction at week 4 and 12.
Finally, EPO rs1617640 G homozygotes had a significantly
higher need of RBV dose reduction or epoetin-α supple-
mentation, but not blood transfusion. The reason for this
might be the relatively small sample number of patients
who achieved blood transfusion.
Although this study investigated the EPO rs1617640
SNP with regard to a common side effect such as Hb
Table 2 Variables associated with Hb reduction > 3 g/dl
Univariate analysis Multivariate analysis
Characteristics Odds ratio [95% CI] P value Odds ratio [95% CI] P value
Week 4
EPO rs1617640 (GG vs. TT/TG) 1.66 [0.92 – 2.94] 0.088 2.17 [1.09 – 4.30] 0.025
ITPA rs1127354 (additive) 0.35 [0.15 – 0.71] 0.007 0.32 [0.13 – 0.70] 0.007
Age (years) 0.97 [0.95 – 0.99] 0.0085 0.97 [0.95 – 1.00] 0.02
Sex (female vs. male) 0.75 [0.44 – 1.26] 0.285 1.64 [0.88 – 3.07] 0.12
Baseline Hb (g/dl) 2.24 [1.76 – 2.92] < 0.001 2.50 [1.91 – 3.34] < 0.001
RBV starting dose* 2.49 [1.03 – 7.34] 0.011 2.50 [1.03 – 7.34] 0.036
Week 12
EPO rs1617640 (GG vs. TT/TG) 1.57 [0.92 – 2.70] 0.064 1.97 [1.07 – 3.66] 0.029
ITPA rs1127354 (additive) 0.60 [0.35 – 1.01] 0.058 0.58 [0.32 – 1.03] 0.067
Age (years) 0.97 [0.95 – 0.99] 0.002 0.97 [0.95 – 0.99] 0.004
Sex (female vs. male) 0.86 [0.55 – 1.33] 0.49 1.75 [1.04 – 2.99] 0.084
Baseline Hb (g/dl) 1.90 [1.55 – 2.35] < 0.001 2.08 [1.67 – 2.64] < 0.001
RBV starting dose* 2.09 [1.20 – 3.79] 0.011 2.18 [1.17 – 4.20] 0.016
Abbreviations: EPO erythropoietin, ITPA inosine triphosphatase, RBV ribavirin, CI confidence interval. *RBV starting dose is coded as an ordered categorical variable
with levels of 800, 1000, 1200, and 1400 mg with linear increments.
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Figure 3 Linear regression analysis of serum EPO levels and Hb levels at week 4. This analysis revealed an inverse relationship between the
increase of serum EPO levels and the decline of Hb levels in 112 patients of whom data on serum EPO levels were available (A). This relationship
is valid for carriers of the T allele (C) but not for G homozygous patients (B). Correlation coefficients and levels of significance are given.
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decline of antiviral therapy in CHC patients, our findings
might not be specific for therapy of CHC with RBV. This
SNP might directly be involved in the regulation of the
EPO response to acute Hb decline in other conditions as
well. Here, the role of RBV might just be in inducing an
“erythropoietic stress test” taking advantage of “con-
trolled conditions” which are not typically achievable in
human research. Therefore, further research (basic and
clinical) should investigate the role of the EPO gene vari-
ation in various anemic diseases.
Interestingly, the Hb levels of EPO rs1617640 G ho-
mozygotes who were treated with epoetin-α remained
stable between weeks 4 to 12. This observation suggests
that substitution of EPO in patients whose EPO gene ac-
tivation appears to be less stimulable than in others for
genetic reasons might be a rational measure and thus
superior to RBV dose reduction.
A genome-wide association study has described gen-
etic variants that are associated with a decrease of
Hb during antiviral combination therapy at week 4 [14].
This genome-wide association study (GWAS), however,
did not report associations between Hb reduction
and any SNP within the EPO gene. Indeed, the EPO
rs1617640 was not present on the Illumina Human610-
quad BeadChips. The only SNP in relative high linkage
(r2: 0.865) with the EPO rs1617640 was rs221795 at a
34,037 basepair distance (http://www.broadinstitute.org/
mpg/snap/). Moreover, GWASs are necessarily broad in
scope. They search the entire genome for associations
rather than focusing on small candidate areas and they
do not necessarily identify all relevant SNPs [36]. Fur-
thermore, all GWAS that evaluated SNPs for Hb decline
while on treatment for CHC focused on end points at
week 4 and could therefore only evaluate gene variations
for short term Hb decline but not mid- to long-term Hb
decline. This analysis shows that particularly short term
Hb decline associates with ITPA gene variant while
longer-term Hb decline appears to relate on EPO gene
variant. This hypothesizes that short and long-term Hb
decline on treatment for HCV may have somewhat dif-
ferent mechanisms.
The effect of baseline Hb on the reduction of Hb on
treatment is explainable by the hypothesis that reduction
of Hb due to RBV is relative and not absolute. Therefore
higher baseline Hb is associated with higher incidence of
Hb reduction of more than 3 g/dl, because a reduction of
3 g/dl is equivalent to 19% reduction when the baseline
Hb is 16 g/dl but 23% when the baseline Hb is 13 g/dl. On
the other side when the end-point is formulated as Hb re-
duction below 10 g/dl a higher baseline Hb is associated
with a lower risk to reach this endpoint (for the same rea-
sons). Furthermore, age is also a well-known risk factor
for Hb reduction during antiviral therapy [37,38].
The obvious constraint of this analysis is that this is a
retrospective and explorative analysis of a registry data
and not a formal trial. For this purpose EPO rs1617640
polymorphism should be evaluated in a prospective trial.
Nevertheless, the consistency of these multiple analyses
and results, i.e. association of EPO gene variant with
lower serum erythropoietin increase, a higher risk of Hb
reduction, and higher incidence of adverse events sug-
gests that EPO may indeed play an hitherto unheralded
role in the treatment of CHC.
In terms of new therapeutic options, especially in light
of IFN-free regimens, 5% to 9% of patients who were
treated with a DAA- and RBV-containing regimen
showed increased Hb decline (<10 g/dl) compared to
those who were not treated with a RBV-containing regi-
men [39-43]. Therefore, also for IFN-free regimens with
RBV, EPO rs1617640 genotyping might be worth to be
valuated for estimating a risk for a marked Hb decline.
A need to terminate these new and costly treatment op-
tions because of serious Hb declines is critical not least
in view of inhibitor-resistance mutations.
Table 3 Cumulative proportion of Hb reconstitution
measures with regard to EPO and ITPA genotypes
EPO rs1617640 GG (n = 27) 40% P < 0.001
GT/TT (n = 39) 14%
ITPA rs1127354 CC (n = 58) 21% P = 0.079
CA/AA (n = 8) 12%
Abbreviations: Hb hemoglobin, EPO erythropoietin, ITPA inosine triphosphatase.
Table 4 Variables associated with the combined clinical endpoint of RBV dose reduction, transfusion of erythrocyte
concentrates, or administration of epoetin-α
Univariate analysis Multivariate analysis
Characteristics Odds ratio [95% CI] P value Odds ratio [95% CI] P value
EPO rs1617640 (GG vs. TT/TG) 4.19 [2.31 – 7.59] < 0.001 4.14 [2.20 – 7.82] < 0.001
Sex (female vs. male) 0.45 [0.24 – 0.83] 0.013 0.41 [0.21 – 0.80] 0.003
Baseline Hb (g/dl) 0.87 [0.70 – 1.09] 0.24 0.83 [0.65 – 1.07] 0.168
RBV start dose* 1.21 [1.04 – 1.40] 0.012 1.18 [1.01 – 1.39] 0.036
Abbreviations: EPO erythropoietin, ITPA inosine triphosphatase, RBV ribavirin, CI confidence interval. *RBV starting dose is coded as a continuous variable with an
intercept at 800 and an increase of 1 in the model corresponding to 100 mg increase of the actual dose.
Amanzada et al. BMC Infectious Diseases 2014, 14:503 Page 8 of 10
http://www.biomedcentral.com/1471-2334/14/503
Conclusion
EPO promoter rs1617640 genotypes, serum EPO con-
centration and ITPA rs1127354 genotypes might be
promising parameters to be further evaluated in view of
a risk assessment for Hb decline and the individuals’
capacity for an EPO response in IFN-α- and RBV-based
therapy regimes.
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